These 2 FTSE 100 dividend and growth heroes are the “stocks of the millennium”

Harvey Jones says the FTSE 100’s (INDEXFTSE: UKX) two millennium superstars are now available at bargain valuations.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Everybody loves a winner. If you have these two FTSE 100 stocks in your portfolio, congratulations, you couldn’t have chosen better. The question now is whether they will continue to deliver over the next 18 years.

BATS out of hell

Stock of the millennium is British American Tobacco (LSE: BATS) according to new research from investment platform AJ Bell. Since 31 December 1999 it has grown a whopping 1,008%, assuming all dividends reinvested for growth. This may come as a surprise to some, because in many respects tobacco is a dying industry. At the start of the millennium, 26.8% of UK adults and 23.2% in the US were smokers. By 2016, those figures had fallen to 15.5% and 15.1% respectively.

It is a different story in China where 30% of adults smoke, including 53% of men. Overall volumes are still falling despite emerging market demand, but British American Tobacco has pricing power and is migrating smokers to higher-margin products. It also has a dominant market position after last year’s acquisition of Reynolds American Inc.

Smoke and fire

Some investors do not touch tobacco but if you do, the case for British American Tobacco remains strong with forecast margins of 38.9% and a 301% return on capital employed. It throws off cash, which it returns to shareholders through share buybacks and its juicy dividend. This has grown every year since 1999, and currently offers a forecast yield of 5% for 2018, with cover of 1.5. Smoking is addictive, giving company and investors a safety net if the global economy slips up. It is also cashing in on the growing popularity of e-cigarettes.

British American Tobacco’s earnings per share (EPS) are forecast to rise 6% this year and 9% in 2019, and it looks a bargain trading at 13.7 times earnings. Market volatility has knocked its share price, which is down almost 22% over the past year, but this looks like a buying opportunity to me.

Household goodie

We don’t need another hero – oh yes we do! Household goods giant Reckitt Benckiser Group (LSE: RB) is the FTSE 100’s second greatest millennium star, returning a total of 922% so far. Air Wick, Dettol, Durex, Finish, Harpic, Nurofen, Vanish are just some of the reasons why.

Performance has disappointed lately, with growth trailing rival Unilever. Problems include £300m consumer redress in Korea, a US Department of Justice investigation, and last year’s cyber attack. Management also has its work cut out turning around recent acquisition, formula milk specialist Mead Johnson, although £300m of cost synergies by 2020 gives it a juicy target to aim at.

Recovery play

The long-term story is rock solid, despite recent shaky news flow. The share price is down 17% in the last year as a result, and again, I see a buying opportunity. Reckitt Benckiser trades at a forecast 18.2 times earnings, bargain territory for this stock, which routinely knocks around the 25 mark.

The future looks bright for this bargain defensive stock with EPS forecast to grow 5% this year and 7% in 2019, lifting the yield to 3%. I expect the success story to continue. The recent dip allows you to jump on board at a decent price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Up 12% today, here’s a great FTSE 250 growth share to consider!

Softcat's share price is soaring following a blockbuster first-half trading announcement. Here's why the FTSE 250 share is worth a…

Read more »

Growth Shares

Prediction: in 1 year, the easyJet share price could be as high as…

Jon Smith points out why the easyJet share price could head higher over the coming year based on the current…

Read more »

Investing Articles

Up 21% with dividends on top! See the stunning Shell share price forecast for 2025

Brokers are feeling optimistic about the outlook for the Shell share price, predicting solid growth this year. But Harvey Jones…

Read more »

Investing Articles

£10,000 invested in AstraZeneca shares 1 year ago is now worth…

AstraZeneca shares have recovered from their brief slump with investors broadly buoyed by the company’s long-term business prospects.

Read more »

Investing Articles

What’s going on with Nvidia stock?

Nvidia stock has slumped, and it seems that CEO Jensen Huang may have lost the Midas touch after his AI…

Read more »

Investing For Beginners

Starting at 46, how much would need to be invested in the FTSE 100 to have £445k by retirement?

Jon Smith provides a rundown of the strategy, specific ideas and the numbers involved to grow a FTSE 100 portfolio…

Read more »

Investing Articles

3 top AIM stocks to consider buying before they recover

AIM stocks aren't for faint-hearted investors. But here are three high-quality examples for the risk-tolerant to ponder buying while they're…

Read more »

Black father and two young daughters dancing at home
Investing Articles

The M&G share price soars 5% as it raises its dividend outlook despite £1.9bn in outflows

The M&G share price was given a boost this morning after its full-year results revealed a progressive dividend policy. Our…

Read more »